These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 1280862)

  • 1. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of plasmin catalyzed conversion of single-chain to two-chain urokinase-type plasminogen activator by sulfated polysaccharides.
    Rydzewski A; Takada Y; Takada A
    Thromb Haemost; 1989 Sep; 62(2):752-5. PubMed ID: 2479114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects.
    de Boer A; Kluft C; Gerloff J; Dooijewaard G; Günzler WA; Beier H; van der Meer FJ; Cohen AF
    Thromb Haemost; 1993 Aug; 70(2):320-5. PubMed ID: 8236142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin and heparan sulfate enhancement of the inhibitory activity of plasminogen activator inhibitor type 1 toward urokinase type plasminogen activator.
    Urano T; Serizawa K; Takada Y; Ny T; Takada A
    Biochim Biophys Acta; 1994 Nov; 1201(2):217-22. PubMed ID: 7947934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma.
    Dooijewaard G; de Boer A; Turion PN; Cohen AF; Breimer DD; Kluft C
    Thromb Haemost; 1991 Jan; 65(1):82-6. PubMed ID: 1902597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
    Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
    Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells.
    Marsh NA; Minter AJ; Chesterman CN
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):133-8. PubMed ID: 1966669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
    Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
    J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors.
    Mukherjee M; Sembhi K; Kakkar VV
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):491-6. PubMed ID: 8840003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J; Binder BR; Huber K; Hoover RL
    Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.